A BILL 
To improve diversity in clinical trials and data collection 
for COVID–19 and future public health threats to ad-
dress social determinants of health. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Diversifying Investiga-
4
tions Via Equitable Research Studies for Everyone Trials 
5
Act’’ or the ‘‘DIVERSE Trials Act’’. 
6
01:56 Aug 14, 2021
H5030
2 
•HR 5030 IH
SEC. 2. GUIDANCE ON DECENTRALIZED CLINICAL TRIALS. 
1
(a) DEFINITIONS.—In this section, the term ‘‘decen-
2
tralized clinical trials’’ includes clinical trials that are exe-
3
cuted through a broad spectrum of options, such as tele-
4
medicine or other mobile or digital technologies, to allow 
5
for the remote collection and assessment of clinical trial 
6
data from participants, including in the home or office set-
7
ting. 
8
(b) GUIDANCE.—Not later than 6 months after the 
9
date of enactment of this Act, the Secretary of Health and 
10
Human Services (referred to in this Act as the ‘‘Sec-
11
retary’’), acting through the Commissioner of Food and 
12
Drugs (referred to in this Act as the ‘‘Commissioner’’), 
13
shall issue a draft guidance that addresses how to conduct 
14
decentralized clinical trials with meaningful demographic 
15
diversity, including racial, ethnic, age, gender, and geo-
16
graphic diversity in patient engagement, enrollment, and 
17
participation, including how to appropriately use digital 
18
health technologies or other remote assessment options, 
19
such as telemedicine, to support such trials. Not later than 
20
6 months after the date the public comment period for 
21
the draft guidance ends, the Secretary shall issue a final 
22
guidance. 
23
(c) CONTENT OF GUIDANCE.—The guidance under 
24
subsection (b) shall address the following: 
25
01:56 Aug 14, 2021
H5030
3 
•HR 5030 IH
(1) Strategies to engage with prospective clin-
1
ical trial participants and community partners, such 
2
as patient advocacy groups with diverse representa-
3
tion, to incorporate input of such patients and part-
4
ners into the design of decentralized clinical trials. 
5
(2) Recommendations for— 
6
(A) protocol design approaches; 
7
(B) appropriate clinical endpoints; 
8
(C) institutional review board composition 
9
and ensuring that such boards include members 
10
with expertise in decentralized clinical trials; 
11
(D) delegation of clinical research organi-
12
zation responsibilities and suitable proxies for 
13
clinical research organizations; and 
14
(E) simplifying informed consent. 
15
(3) Recommendations for how digital health 
16
technology or other remote assessment options, such 
17
as telemedicine, could support decentralized clinical 
18
trials, including guidance on appropriate techno-
19
logical platforms and mediums, data collection and 
20
use, data integrity, and communication to study par-
21
ticipants through digital technology. 
22
(4) Recommendations for appropriate methods 
23
of patient recruitment and retention, including insti-
24
tutional review board oversight, patient communica-
25
01:56 Aug 14, 2021
H5030
4 
•HR 5030 IH
tion, and the role of study participants and commu-
1
nity partners as advocates to facilitate clinical trial 
2
recruitment, particularly with respect to underrep-
3
resented populations. 
4
(5) Information regarding when and how a 
5
study sponsor may solicit a meeting with the Sec-
6
retary regarding the issues described in paragraphs 
7
(1) through (4). 
8
(d) 
INTERNATIONAL
HARMONIZATION.—After 
9
issuing the final guidance under subsection (b), the Sec-
10
retary, acting through the Commissioner, may work with 
11
foreign regulators pursuant to existing memoranda of un-
12
derstanding governing exchange of information to facili-
13
tate international harmonization of the regulation of de-
14
centralized clinical trials and use of digital health tech-
15
nology or other remote assessment options. 
16
SEC. 3. ENCOURAGEMENT OF CLINICAL TRIAL ENROLL-
17
MENT BY RACIALLY AND ETHNICALLY DI-
18
VERSE POPULATIONS. 
19
(a) NO COST PROVISION OF DIGITAL HEALTH TECH-
20
NOLOGIES.—The free provision of digital health tech-
21
nologies by drug or device manufacturers to their clinical 
22
trial participants shall not be considered a violation of sec-
23
tion 1128A of the Social Security Act (commonly known 
24
as the ‘‘Civil Monetary Penalties Law’’) (42 U.S.C. 
25
01:56 Aug 14, 2021
H5030
5 
•HR 5030 IH
1320a–7a), section 1128B of the Social Security Act (42 
1
U.S.C. 1320a–7b), or sections 3729 through 3733 of title 
2
31, United States Code, (commonly known as the ‘‘False 
3
Claims Act’’), provided that— 
4
(1) the use of digital health technologies will fa-
5
cilitate in any phase of clinical development the in-
6
clusion of diversity of patient populations, such as 
7
underrepresented racial and ethnic minorities, low- 
8
income populations, and the elderly; 
9
(2) the digital health technologies will facilitate 
10
individuals participation, or are necessary to such 
11
participation; 
12
(3) all features of the digital health technologies 
13
that are unrelated to use in the clinical trial are dis-
14
abled or only allowed to remain activated to model 
15
real-world usage of the digital technology; and 
16
(4) the clinical trial sponsor requires partici-
17
pants to return, purchase, or disable the digital 
18
health technologies by the conclusion of the trial. 
19
(b) GRANTS AND CONTRACTS.— 
20
(1) IN
GENERAL.—The Secretary may issue 
21
grants to and enter into contracts with entities to 
22
support community education, outreach, and recruit-
23
ment activities for clinical trials with respect to 
24
drugs, including vaccines for diseases or conditions 
25
01:56 Aug 14, 2021
H5030
6 
•HR 5030 IH
which have a disproportionate impact on underrep-
1
resented populations (including on racial and ethnic 
2
minority populations), including for the diagnosis, 
3
prevention, or treatment of COVID–19. Such activi-
4
ties may include— 
5
(A) working with community clinical trial 
6
sites, including community health centers, aca-
7
demic health centers, and other facilities; 
8
(B) training health care personnel includ-
9
ing potential clinical trial investigators, with a 
10
focus on significantly increasing the number of 
11
underrepresented racial and ethnic minority 
12
healthcare personnel who are clinical trial inves-
13
tigators at the community sites for ongoing 
14
clinical trials; 
15
(C) engaging community stakeholders to 
16
encourage participation in clinical trials, espe-
17
cially in underrepresented racial and ethnic mi-
18
nority communities; and 
19
(D) fostering partnerships with commu-
20
nity-based 
organizations 
serving 
underrep-
21
resented racial and ethnical minority popu-
22
lations, including employee unions and frontline 
23
health care workers. 
24
01:56 Aug 14, 2021
H5030
7 
•HR 5030 IH
(2) PRIORITY
FOR
GRANT
AND
CONTRACT 
1
AWARDS.—In awarding grants and contracts under 
2
this subsection, the Secretary shall prioritize entities 
3
that— 
4
(A) develop educational, recruitment, and 
5
training materials in multiple languages; or 
6
(B) undertake clinical trial outreach efforts 
7
in more diverse racial and ethnic communities 
8
that are traditionally underrepresented in clin-
9
ical trials, such as tribal areas. 
10
(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
11
There is authorized to be appropriated for fiscal 
12
years 2020 and 2021 such sums as may be nec-
13
essary to carry out this subsection. 
14
SEC. 4. ENHANCEMENT OF COVID–19 DATA COLLECTION TO 
15
ADDRESS DEMOGRAPHIC DATA GAPS AND SO-
16
CIAL DETERMINANTS OF HEALTH. 
17
(a) DATA COLLECTION TO ADDRESS DEMOGRAPHIC 
18
DATA GAPS.— 
19
(1) IN GENERAL.—The Secretary shall require 
20
laboratories that are subject to the reporting re-
21
quirements 
under 
section 
18115(a) 
of 
the 
22
Coronavirus Aid, Relief, and Economic Security Act 
23
(Public Law 116–136), to include with reports made 
24
under such section 18115(a) information to enhance 
25
01:56 Aug 14, 2021
H5030
8 
•HR 5030 IH
such existing COVID–19 data collection activities 
1
and to advance policies to address social deter-
2
minants of health, including additional identifiers, 
3
such as those identified by the Commissioner, in-
4
cluding building on guidance existing on the date of 
5
enactment of this Act, for the collection of race and 
6
ethnicity data in clinical trials, as determined appro-
7
priate by the Secretary. 
8
(2) ADDITIONAL USE OF DATA.—The data col-
9
lected under paragraph (1) may be used to inform— 
10
(A) clinical trial recruitment; 
11
(B) resource allocations; 
12
(C) treatment strategies; and 
13
(D) other public health activities. 
14
(3) COLLECTION VIA GRANTS OR CONTRACTS.— 
15
(A) IN
GENERAL.—The Secretary may 
16
issue grants to, and enter into contracts with, 
17
States, local public health departments, or other 
18
entities supplying data to the Secretary as re-
19
quired under this subsection, to support the ac-
20
tivities under this subsection. 
21
(B) GUIDANCE FOR USE OF FUNDS.—In 
22
issuing grants or contracts under subparagraph 
23
(A), the Secretary may issue guidance regard-
24
ing best practices for collecting data pursuant 
25
01:56 Aug 14, 2021
H5030
9 
•HR 5030 IH
to paragraph (1) and track the performance of 
1
entities receiving grants or contracts. 
2
(4) USE AND DISCLOSURE FOR PUBLIC HEALTH 
3
ACTIVITIES.—The submission and use of data col-
4
lected pursuant to this subsection shall be consid-
5
ered a permitted disclosure and use for public health 
6
activities as set forth in section 164.512(b)(1)(i) of 
7
45, Code of Federal Regulations (or any successor 
8
regulations). 
9
(b) DATA COLLECTION REGARDING ENHANCED RISK 
10
FOR COVID–19.—The Secretary shall— 
11
(1) conduct a study on best practices for lab-
12
oratories that are subject to the reporting require-
13
ments under section 18115(a) of the Coronavirus 
14
Aid, Relief, and Economic Security Act (Public Law 
15
116–136) to aid such laboratories in collecting data 
16
elements related to enhanced risk for COVID–19, 
17
such as data, with respect to a patient, regarding in-
18
come, education, employment, disability, community 
19
resources, and social support; 
20
(2) consider which governmental entities (in-
21
cluding Federal, State, and local governmental enti-
22
ties) would be best suited to aiding in collecting such 
23
data elements in coordination with such laboratories; 
24
and 
25
01:56 Aug 14, 2021
H5030
10 
•HR 5030 IH
(3) issue guidance on such best practices. 
1
SEC. 5. CLARIFICATION THAT CERTAIN REMUNERATION 
2
RELATED TO PARTICIPATION IN CLINICAL 
3
TRIALS DOES NOT CONSTITUTE REMUNERA-
4
TION UNDER THE FEDERAL CIVIL MONEY 
5
PENALTIES LAW. 
6
(a) IN GENERAL.—Section 1128A(i)(6)(F) of the So-
7
cial Security Act (42 U.S.C. 1320a–7a(i)(6)(F)) is amend-
8
ed by inserting ‘‘(including remuneration offered or trans-
9
ferred to an individual to promote the participation in an 
10
approved clinical trial, as defined in subsection (d) of the 
11
first section 2709 of the Public Health Service Act, that 
12
is registered with the database of clinical trials maintained 
13
by the National Library of Medicine (or any successor 
14
database), so long as such remuneration facilitates equi-
15
table inclusion of patients from all relevant demographic 
16
and socioeconomic populations and is related to patient 
17
participation in the approved clinical trial)’’ after ‘‘pro-
18
motes access to care’’. 
19
(b) EFFECTIVE DATE.—The amendment made by 
20
subsection (a) shall apply to remuneration provided on or 
21
after the date of the enactment of this Act. 
22
SEC. 6. NATIONAL ACADEMY OF MEDICINE STUDY. 
23
(a) IN GENERAL.—The Secretary shall enter into an 
24
arrangement with the National Academy of Medicine 
25
01:56 Aug 14, 2021
H5030
11 
•HR 5030 IH
under which the National Academy agrees to study and 
1
propose a design for a national interoperable data plat-
2
form to improve access to health data, and other relevant 
3
data needs, during public health emergencies. 
4
(b) REPORT.—The arrangement under subsection (a) 
5
shall provide for submission by the National Academy of 
6
Medicine to the Secretary and Congress, not later than 
7
120 days after the date of enactment of this Act, of a 
8
report on the results of the study under subsection (a) 
9
and the design proposed based on such study. 
10
Æ 
01:56 Aug 14, 2021
H5030
